MX2022000815A - Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia. - Google Patents

Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia.

Info

Publication number
MX2022000815A
MX2022000815A MX2022000815A MX2022000815A MX2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A MX 2022000815 A MX2022000815 A MX 2022000815A
Authority
MX
Mexico
Prior art keywords
antibody
immunotherapy
sting agonist
agonist conjugates
conjugates
Prior art date
Application number
MX2022000815A
Other languages
English (en)
Inventor
Zhijian Chen
Lijun Sun
Heping Shi
Chuo Chen
Qi Wei
Jian Qiu
youtong Wu
Original Assignee
Immunesensor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunesensor Therapeutics Inc filed Critical Immunesensor Therapeutics Inc
Publication of MX2022000815A publication Critical patent/MX2022000815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere, entre otras cosas, a conjugados anticuerpo-fármaco que comprenden un dinucleótido cíclico agonista de STING conjugado con un anticuerpo, métodos de preparación y usos de los mismos.
MX2022000815A 2019-07-19 2020-07-20 Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia. MX2022000815A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876590P 2019-07-19 2019-07-19
US202063019212P 2020-05-01 2020-05-01
PCT/US2020/042815 WO2021016204A1 (en) 2019-07-19 2020-07-20 Antibody-sting agonist conjugates and their use in immunotherapy

Publications (1)

Publication Number Publication Date
MX2022000815A true MX2022000815A (es) 2022-05-03

Family

ID=71995149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000815A MX2022000815A (es) 2019-07-19 2020-07-20 Conjugados de anticuerpo-agonista de sting y su uso en inmunoterapia.

Country Status (13)

Country Link
US (3) US11033635B2 (es)
EP (1) EP3999118A1 (es)
JP (1) JP2022541517A (es)
KR (1) KR20220054794A (es)
CN (2) CN117838878A (es)
AU (1) AU2020315802A1 (es)
BR (1) BR112022000854A2 (es)
CA (1) CA3147890A1 (es)
IL (1) IL289866A (es)
MX (1) MX2022000815A (es)
TW (1) TW202116358A (es)
WO (1) WO2021016204A1 (es)
ZA (1) ZA202201988B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999118A1 (en) * 2019-07-19 2022-05-25 Immunesensor Therapeutics, Inc. Antibody-sting agonist conjugates and their use in immunotherapy
WO2022225827A1 (en) * 2021-04-21 2022-10-27 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
CA3233464A1 (en) * 2021-10-04 2023-04-13 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof
TW202342105A (zh) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途
CN117343111B (zh) * 2023-12-04 2024-02-06 康羽生命科学技术(苏州)有限公司 核苷修饰物n2-异丁酰-2'-甲氧基鸟苷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
IN2014CN04961A (es) 2011-12-05 2015-09-18 Igenica Biotherapeutics Inc
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP3334745B1 (en) * 2015-08-13 2024-05-15 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
WO2017100305A2 (en) 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof
GB2552041A (en) * 2015-12-07 2018-01-10 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods thereof
KR102530488B1 (ko) 2016-03-18 2023-05-08 이뮨 센서, 엘엘씨 사이클릭 디-뉴클레오티드 화합물 및 사용 방법
EP3922279A1 (en) 2016-08-30 2021-12-15 Dana Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
RU2019122598A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
EP3999118A1 (en) * 2019-07-19 2022-05-25 Immunesensor Therapeutics, Inc. Antibody-sting agonist conjugates and their use in immunotherapy

Also Published As

Publication number Publication date
BR112022000854A2 (pt) 2022-03-08
CA3147890A1 (en) 2021-01-28
CN114786729A (zh) 2022-07-22
TW202116358A (zh) 2021-05-01
ZA202201988B (en) 2023-10-25
US11213592B2 (en) 2022-01-04
US20220105198A1 (en) 2022-04-07
EP3999118A1 (en) 2022-05-25
KR20220054794A (ko) 2022-05-03
WO2021016204A1 (en) 2021-01-28
US20210015941A1 (en) 2021-01-21
IL289866A (en) 2022-03-01
US11033635B2 (en) 2021-06-15
CN117838878A (zh) 2024-04-09
CN114786729B (zh) 2023-12-19
US20210290774A1 (en) 2021-09-23
JP2022541517A (ja) 2022-09-26
AU2020315802A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
ZA202201988B (en) Antibody-sting agonist conjugates and their use in immunotherapy
MX2020013169A (es) Conjugados de camptotecina.
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
MX2021002575A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
MX2020006409A (es) Moléculas de unión al antígeno específicas para ror1.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2016002150A (es) Anticuerpos anti-prlr y usos de los mismos.
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
MX2018015271A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MY170719A (en) Antibody-drug conjugates
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MY148763A (en) Anti-5t4 antibodies and uses thereof
PH12016501816B1 (en) Antibody-fynomer conjugates
EP4269441A3 (en) Il-15 and il-15ralpha sushi domain based on modulokines
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
MX2015012549A (es) Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
NZ703581A (en) Anti-cd70 antibody drug conjugates
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MY171841A (en) Antibody formulation
MX2010007767A (es) Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
EP3808773A4 (en) AXL-TARGETING ANTIBODY, ANTIBODY-DRUG CONJUGATE, METHOD FOR PREPARING IT, AND USE THEREOF
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
MX2015002482A (es) Composicion inmunogenica.
CL2020000977A1 (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos.
EP3735271A4 (en) ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS